Correction to: Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants In Patients With Atrial Fibrillation: The ANATOLIA-AF Study (Cardiovascular Drugs and Therapy, (2022), 10.1007/s10557-022-07409-w)
Makaleler > Tam Makale · 2023
Yazarlar: Umut Kocabaş, Işıl ERGİN, Veysel Yavuz, Selda Murat, Ibrahim Özdemir, Ömer Genç, Cihan Altın, Haşim Tüner, Bengisu Keskin Meriç, Ali Çoner, Elif İlkay Yüce, Bedrettin Boyraz, Onur Aslan, Ahmet Dal, Taner Şen, Ersin İbişoğlu, Aslan Erdoğan, Mehmet Özgeyik, Mevlüt Demir, Ziya Gökalp Bilgel, Büşra Güvendi Şengör, Örsan Deniz Urgun, Mustafa Doğduş, Deniz Dilan Naki Tekin, Sinem Çakal, Sercan Çayırlı, Arda Güler, Dilay Karabulut, Onur Dalgıç, Osman Uzman, Bektaş Murat, Şeyda Şahin, Umut Karabulut, Tarık Kıvrak, Muharrem Said Coşgun, Ferhat Özyurtlu, Mehmet Kaplan, Emre Özçalık
Cardiovascular Drugs and Therapy, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Scopus, 2023
DOI: 10.1007/s10557-023-07427-2
Özet
In the following article published in Cardiovascular Drugs and Therapy, December 17, 2022, the subtitle of Table 1 included an incorrect phrase: “For patients receiving rivaroxaban or for patients receiving apixaban or for patients receiving edoxaban.” This has been deleted and replaced with the correction subheading “For patients receiving dabigatran.”